U Posted by Laura Moller
\ January 17, 2014

Novuson Surgical’s patented Focused Ultrasound surgical tool technology allows for rapid, precise, and automated surgeries. Their technology is the first and only of its kind and dramatically reduces surgery times, improves patient outcomes, and drives significant cost savings for the healthcare system. Adoption of a single Novuson system will save a hospital over $1.2M annually in direct costs.

The Novuson Surgical team has established scientific credibility via compelling proof of concept trials during the past 9 years. Novuson has been granted 7 U.S. utility patents, 2 of which have been extended internationally, and has been awarded over $3 million in grant funding from the National Institute of Health.

The team is now transitioning from a R&D company to a manufacturing and marketing company, delivering product systems at a national then global scale. Their next step is to integrate the lab prototype into a product-ready clinical system suitable for 510(k)clearance by the FDA and use in human trials.

Learn more about what’s to come for Novuson Surgical and view their Fundable profile here.

No comments yet.

Ready to Start Raising Capital?


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service funding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.